Commentary
Video
Author(s):
Milind Javle, MD; Rachna Shroff, MD, MS, FASCO; and a patient discuss considering factors for immunotherapy agents in advanced biliary tract cancer.
State of Science Summit: Gastrointestinal Cancer - Chaired by: Tanios Bekaii-Saab, MD and Darshil Shah, MD, MPH
Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress
ODAC Votes Against Risk:Benefit Profile of Frontline Anti–PD-1 Therapy in Metastatic/Unresectable ESCC With a PD-L1 Expression Under 1
Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
FDA Grants Fast Track Status to EO-3021 for CLDN18.2-Expressing Gastric or GEJ Cancer
Phase 2 Data Point to Potential Predictive Biomarkers for Benefit With Second-Line CM24 Combo in PDAC
MRD Negativity Is Sustained After Cessation of Lenalidomide Maintenance in Multiple Myeloma
Locally Produced CAR T-Cell Therapy Elicits 92% ORR in Relapsed/Refractory Myeloma
Dr Dhakal on Survival and Safety Outcomes With Cilta-Cel in R/R Myeloma
Dr Corre on MRD Negativity With D-VTd Induction/Consolidation in Newly Diagnosed Multiple Myeloma